IRCT20090117001556N150 IRCT 2023-04-24 Tehran University of Medical Sciences The effect of rosiglitazone in the treatment of autism Rosiglitazone as an adjuvant therapy to risperidone in children with autism spectrum disorder: a randomized placebo-controlled double-blind clinical trial 2023-06-22 anticipated 50 Complete https://irct.ir/trial/69657 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization: using A and B blocks with n=4; AABB, ABAB, ABBA, BABA, BAAB, BBAA. We randomly use the blocks to achieve total sample size. ("A" and "B" are the study groups), Blinding description: The participants, care providers and outcome assessors will be blind regarding grouping. All the participants believe that they are taking the main medication (the participants who are taking placebo are not aware of it). Care providers and outcome assessors do not know which participants have received the main medication and which participants have received placebo. Thus, there is no orientation in their work process. 2-3 Autistic disorder. Intervention 1: Control group: Children with autism received daily risperidone (0.5 mg per day, and 0.5 mg added up to seven days, up to a maximum dose of 3 mg per day) and placebo for 10 weeks. Intervention 2: Intervention group: Children with autism receive daily risperidone (0.5 mg per day, and 0.5 mg added up to seven days, up to a maximum dose of 3 mg per day) and rosiglitazone (4 mg in two doses) for 10 weeks.​. Yes - There is a plan to make this available What will be shared: The data will be distributed through final report When: 5 years from 2023 to 2028 To whom: Academic researchers Conditions: Users should cite the resource of data Where to obtain: Prof. Shahin Akhondzadeh How to obtain: By E-mail Comments: